To investigate the screening efficacy of six thrombotic markers for hypercoagulable state (HCS) in pregnant women, including thrombin–antithrombin III complex (TAT), plasmin-alpha-2 plasmin inhibitor complex (PIC), thrombomodulin (TM), tissue-type plasminogen activator inhibitor complex(t-PAI-C), D-dimer(D-D), and fibrinogen degradation products (FDP). The gene discussed is THBD; the disease is thrombophilia.